LXRX stock news
This page provides real-time market news, earnings updates, and company announcements related to Lexicon Pharmaceuticals, Inc. (LXRX).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-13 08:56 EST
Trump's Iran tariff threat risks reopening China rift
101 finance2026-01-13 10:57:22
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Finviz2026-02-26 13:33:10
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations
101 finance2026-03-04 14:19:13
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Finviz2026-03-05 12:03:12
Lexicon: Q4 Financial Results Overview
101 finance2026-03-05 12:27:13
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Finviz2026-03-10 16:34:27
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Finviz2026-03-11 12:03:50
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Finviz2026-03-23 11:33:56
Novo Nordisk experiences a 42% decrease in volume and falls to 229th place as its GLP-1 market share declines compared to Eli Lilly
101 finance2026-03-23 23:36:43
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Finviz2026-03-24 12:03:49
LXRX Shares Rise After NVO Begins Phase I Trial for Collaborative Obesity Medication
101 finance2026-03-24 15:39:38
Lexicon: Q4 Financial Results Overview
101 finance2026-03-05 12:27:13
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Finviz2026-03-10 16:34:27
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Finviz2026-03-11 12:03:50
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Finviz2026-03-23 11:33:56
Novo Nordisk experiences a 42% decrease in volume and falls to 229th place as its GLP-1 market share declines compared to Eli Lilly
101 finance2026-03-23 23:36:43
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Finviz2026-03-24 12:03:49
LXRX Shares Rise After NVO Begins Phase I Trial for Collaborative Obesity Medication
101 finance2026-03-24 15:39:38
LXRX stock chart
LXRX stock detailsLXRX stock price change
On the last trading day, LXRX stock closed at 1.72 USD, with a price change of -2.27% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more